Fluoxetine improves behavioral performance by suppressing the production of soluble β-amyloid in APP/PS1 mice

Current Alzheimer Research

Volumn 11, Issue 7, 2014, Pages 672-680

  Wang, Junhui ^a,b   Zhang, Yanbo ^c   Xu, Haiyun ^d   Zhu, Shenghua ^e   Wang, Hongxing ^e   He, Jue ^b   Zhang, Handi ^a   Guo, Huining ^b   Kong, Jiming ^e   Huang, Qingjun ^a   Li, Xin Min ^b  

^a SHANDONG MENTAL HEALTH CENTER   (China)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Alzheimer's disease (AD); Amyloid precursor protein (APP); Behavior; Fluoxetine; Soluble A

Indexed keywords

AMYLOID BETA PROTEIN; FLUOXETINE; MICROTUBULE ASSOCIATED PROTEIN 2; SYNAPTOPHYSIN; AMYLOID PRECURSOR PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MTAP2 PROTEIN, MOUSE; NOOTROPIC AGENT; SYP PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL RESEARCH; BRAIN TISSUE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG MECHANISM; EMOTION; LEARNING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; SPATIAL MEMORY; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PLAQUE, AMYLOID; PSYCHOLOGY; SPATIAL LEARNING; TRANSGENIC MOUSE; PROTEIN PHOSPHORYLATION; SERUM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; EMOTIONS; FLUOXETINE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; NOOTROPIC AGENTS; PHOSPHORYLATION; PLAQUE, AMYLOID; SPATIAL LEARNING; SPATIAL MEMORY; SYNAPTOPHYSIN;

EID: 84906912513     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140812114715     Document Type: Article

References (46)

1. Fuller S, Steele M, Munch G. Activated astroglia during chronic inflammation in Alzheimer's disease-Do they neglect their neurosupportive roles? Mutat Res-Fund Mol M 690(1-2): 40-49 (2010).
2. Alzheimer's A. 2010 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association 6(2): 158-94 (2010).
3. Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, et al. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 59(4): 568-80 (2008).
4. Shah S, Reichman WE. Treatment of Alzheimer's disease across the spectrum of severity. Clin Interv Aging 1(2): 131-42 (2006).
5. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148(5): 379-97 (2008).
6. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 13(2): 233-40 (2001).
7. Marksteiner J, Walch T, Bodner T, Gurka P, Donnemiller E. Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites. Pharmacopsychiatry 36(5): 207-9 (2003).
8. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Depression and Alzheimer's disease: symptom or comorbidity? Am J Alzheimers Dis Other Demen. 17(6): 338-44 (2002).
9. Keowkase R, Aboukhatwa M, Luo Y. Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59(4-5): 358-65 (2010).
10. Grau-Veciana JM. [Treatment of non cognitive symptoms of Alzheimer's disease]. Revista de neurologia 42(8): 482-8 (2006).
11. Tune LE. Depression and Alzheimer's disease. Depression and anxiety 8(1): 91-5 (1998).
12. Mowla A, Mosavinasab M, Haghshenas H, Borhani Haghighi A. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 27(5): 484-7 (2007).
13. Rozzini L, Chilovi BV, Conti M, Bertoletti E, Zanetti M, Trabucchi M, et al. Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. Int Psychogeriatr 22(1): 114-9 (2010).
14. Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo QX, et al. Genetic Suppression of Transgenic APP Rescues Hypersynchronous Network Activity in a Mouse Model of Alzeimer's Disease. J Neurosci 34(11): 3826-40 (2014).
15. Igelstrom KM. Preclinical antiepileptic actions of selective serotonin reuptake inhibitors--implications for clinical trial design. Epilepsia 53(4): 596-605 (2012).
16. Mazarati A, Siddarth P, Baldwin RA, Shin D, Caplan R, Sankar R. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain: J Neurol 131(Pt 8): 2071-83 (2008).
17. Favale E, Rubino V, Mainardi P, Lunardi G, Albano C. Anticonvulsant Effect of Fluoxetine in Humans. Neurology 45(10): 1926-27 (1995).
18. Ofek K, Schoknecht K, Melamed-Book N, Heinemann U, Friedman A, Soreq H. Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling. J Cell Mol Med 16(11): 2736-44 (2012).
19. Ivkovic M, Damjanovic A, Jasovic-Gasic M, Paunovic VR. The effects of fluoxetine on cognitive functions in animal model of Alzheimer's disease. Psychiatria Danubina 16(1-2): 15-20 (2004).
20. Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Molecular Psychiatry 15(3): 272-85+28 (2010).
21. Liu L, Herukka SK, Minkeviciene R, van Groen T, Tanila H. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis 17(3): 516-23 (2004).
22. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Molecular Psychiatry 13(7): 697-708 (2008).
23. He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, et al. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 30(8): 1205-16 (2009).
24. Zhang W, Wang GM, Wang PJ, Zhang Q, Sha SH. Effects of neural stem cells on synaptic proteins and memory in a mouse model of Alzheimer's disease. J Neurosci Res 92(2): 185-94 (2014).
25. Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 29(47): 14741-51 (2009).
26. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62(6): 788-801 (2009).
27. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-42 (2008).
28. Das U, Scott DA, Ganguly A, Koo EH, Tang Y, Roy S. Activity- Induced Convergence of APP and BACE-1 in Acidic Microdomains via an Endocytosis-Dependent Pathway. Neuron 79(3): 447-60 (2013).
29. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11(11): 1311-8 (2008).
30. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142(2): 320-32 (2010).
31. Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, Greengard P. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. The EMBO J 13(5): 1114-22 (1994).
32. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9): 1553-62 (2005).
33. Rosenberg RN. Immunotherapy for Alzheimer disease: the promise and the problem. Arch Neurol 62(10): 1506-7 (2005).
34. Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62(2): 192-5 (2005).
35. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11(3): 213-28 (2004).
36. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med 4(1): 97-100 (1998).
37. McClean PL, Parthsarathy V, Faivre E, Holscher C. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease. J Neurosci 31(17): 6587-94 (2011).
38. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 27(1): 67-70 (2007).
39. Malm TM, Iivonen H, Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Kanninen K, et al. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci 27(14): 3712-21 (2007).
40. Ramos-Rodriguez JJ, Pacheco-Herrero M, Thyssen D, Murillo-Carretero MI, Berrocoso E, Spires-Jones TL, et al. Rapid beta- amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. J Neuropath Exp Neurol 72(4): 272-85 (2013).
41. Laursen B, Mork A, Plath N, Kristiansen U, Bastlund JF. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice. Behavioural Brain Res 240: 146-52 (2013).
42. Berson A, Knobloch M, Hanan M, Diamant S, Sharoni M, Schuppli D, et al. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain 131: 109-19 (2008).
43. Berson A, Barbash S, Shaltiel G, Goll Y, Hanin G, Greenberg DS, et al. Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice. Embo Mol Med 4(8): 730-42 (2012).
44. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 6(2 Suppl 1): S64-78 (1998).
45. Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc Natl Acad Sci U S A 110(9): 3573-78 (2013).
46. Lee MS, Kao SC, Lemere CA, Xia WM, Tseng HC, Zhou Y, et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163(1): 83-95 (2003).